Xeris Biopharma Holdings, Inc. announced changes to its Board of Directors, with the appointment of James Brady as a new director. Mr. Brady fills a vacancy created by the resignation of Ricki Fairley due to other commitments. Additionally, John Schmid will not seek re-election at the 2025 Annual Stockholders Meeting, which will reduce the Board's size to eight members.
James Brady brings over thirty years of experience from AstraZeneca, where he held various leadership roles in finance, including Chief Financial Officer of MedImmune, AstraZeneca's biologics discovery and development division. His expertise spans corporate operations, manufacturing, commercial, marketing, market access, and international business.
Marla Persky, Chairperson of the Board, stated that Mr. Brady's deep biopharmaceutical industry knowledge and public company financial expertise will be invaluable as Xeris continues its growth journey, drives innovation, and expands its market presence. This appointment aims to enhance the depth and breadth of the board's capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.